Package Leaflet: Information for the Patient
Fesoterodina Intas 4mg prolonged-release tablets EFG
Fesoterodina Intas 8mg prolonged-release tablets EFG
Fesoterodine fumarate
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Fesoterodina Intas contains the active substance fesoterodine fumarate and is a treatment called an antimuscarinic, which reduces the activity of the overactive bladder and is used in adults to treat symptoms.
Fesoterodina treats the symptoms of an overactive bladder, such as:
Do not take Fesoterodina Intas if:
Warnings and precautions
Consult your doctor or pharmacist before starting to take fesoterodine.
Fesoterodina may not always be suitable for you. Talk to your doctor before taking fesoterodina in any of the following cases:
Heart problems: Inform your doctor if you have any of the following conditions:
Children and adolescents
Do not give this medicine to children and adolescents under 18 years of age because it has not been established whether it works and is safe for them.
Other medicines and Fesoterodina Intas
Tell your doctor or pharmacist if you are taking or have recently taken or may need to take other medicines. Your doctor will tell you if you can use fesoterodine with other medicines.
Please inform your doctor if you are taking medicines from the list below.
Taking these medicines at the same time as fesoterodine may cause side effects such as dry mouth, constipation, difficulty emptying the bladder completely, or more severe or frequent drowsiness than usual.
Please indicate to your doctor if you are taking any of the following medicines:
Pregnancy and breastfeeding
You should not take fesoterodine if you are pregnant, as the effects of fesoterodine on pregnancy and the newborn are unknown.
It is not known whether fesoterodine is excreted in breast milk; therefore, do not breastfeed during treatment with fesoterodine.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and using machines
Fesoterodine may cause blurred vision, dizziness, and drowsiness. If you experience any of these effects, do not drive or operate tools or machines.
Fesoterodina Intas contains lactose and soy lecithin
This medicine contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
This medicine contains soy lecithin. Do not use this medicine if you are allergic to peanuts or soy.
Follow exactly the administration instructions of this medicine indicated by your doctor.
In case of doubt, consult your doctor or pharmacist again.
The recommended initial dose of fesoterodine is one 4 mg tablet per day. Depending on how you respond to the medicine, your doctor may prescribe a higher dose; one 8 mg tablet per day.
Swallow the tablet whole with a glass of water. Do not chew the tablet. Fesoterodina can be taken with or without food.
To help you remember to take your medicine, it may be easier to take it at the same time every day.
If you take more Fesoterodina Intas than you should
If you have taken more tablets than you should or if someone else has taken your tablets by mistake, contact your doctor or hospital immediately. Show them the package of the tablets.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take Fesoterodina Intas
If you have forgotten to take a tablet, take it as soon as you remember, but do not take more than one tablet in a day. Do not take a double dose to make up for forgotten doses.
If you stop taking Fesoterodina Intas
Do not stop taking fesoterodine without talking to your doctor first, as the symptoms of an overactive bladder may return or worsen when you stop taking fesoterodine.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some side effects can be serious
Rarely, severe allergic reactions may occur, including angioedema. You should stop taking fesoterodine and contact your doctor immediately if you develop swelling in the face, mouth, or throat.
Other side effects
Very common(may affect more than 1 in 10 people):
You may notice dry mouth. This effect is usually mild or moderate. This may increase the risk of tooth decay. Therefore, you should brush your teeth regularly, twice a day, and visit a dentist if you have any doubts.
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date that appears on the carton and blister after EXP. The expiry date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicine in the SIGRE collection point at the pharmacy. If you have any doubts, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Fesoterodina Intas
Fesoterodina Intas 4mg prolonged-release tablets EFG:
Each prolonged-release tablet contains 4 mg of fesoterodine fumarate, equivalent to 3.1 mg of fesoterodine.
Fesoterodina Intas 8mg prolonged-release tablets EFG:
Each prolonged-release tablet contains 8 mg of fesoterodine fumarate, equivalent to 6.2 mg of fesoterodine.
Core of the tablet:silicon dioxide, microcrystalline cellulose, hypromellose, lactose, and magnesium stearate.
Coating of the 4 mg tablet:poly(vinyl alcohol), titanium dioxide (E171), talc, soy lecithin, yellow iron oxide (E172), and xanthan gum.
Coating of the 8 mg tablet:poly(vinyl alcohol), titanium dioxide (E171), talc, soy lecithin, carmine indigo (E132), and xanthan gum.
Appearance of the product and contents of the pack
Fesoterodina Intas 4mg prolonged-release tablets EFG:
The 4 mg tablets are yellow, oval, 13.2 mm long, and 6.65 mm wide, film-coated, and have the letters "FI" engraved on one side and are smooth on the other.
Fesoterodina Intas 8mg prolonged-release tablets EFG:
The 8 mg tablets are blue, oval, 13.2 mm long, and 6.65 mm wide, film-coated, and have the letters "F II" engraved on one side and are smooth on the other.
Fesoterodina Intas 4 mg and 8 mg are packaged in aluminum-aluminum blisters in a cardboard box containing 28 tablets.
Marketing authorization holder and manufacturer
Marketing authorization holder
Intas Third Party Sales 2005 S.L.
Calle Moll de Barcelona S/N
Edificio World Trade Center
08039 – Barcelona
Spain
Manufacturer
Laboratori Fundació Dau
C/ C, 12-14 Pol. Industrial Zona Franca
08040, Barcelona,
Spain
Date of the last revision of this leaflet: March 2023
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es.